<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513955</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000559820</org_study_id>
    <secondary_id>NCRN-Ply-26s</secondary_id>
    <secondary_id>EU-20747</secondary_id>
    <secondary_id>ISRCTN200600609024</secondary_id>
    <nct_id>NCT00513955</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma</brief_title>
  <official_title>A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Plymouth NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Plymouth NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,
      and prednisolone, work in different ways to stop the growth of cancer cells, either by
      killing the cells or stopping them from dividing. Bortezomib may stop the growth of cancer
      cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy
      together with bortezomib may kill more cancer cells. It is not yet known whether combination
      chemotherapy is more effective with or without bortezomib in treating mantle cell lymphoma.

      PURPOSE: This randomized phase II trial is studying combination chemotherapy and bortezomib
      to see how well they work compared with combination chemotherapy alone in treating patients
      with relapsed or refractory mantle cell lymphoma. Combination chemotherapy alone (Arm I) has
      been discontinued April 2012 on recommendation of the DMC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the rates of overall response (complete response [CR], CR unconfirmed [CRu],
           and partial response).

      Secondary

        -  To evaluate the rates of CR and CRu.

        -  To determine the median time to progression.

        -  To determine the median overall survival.

        -  To evaluate the toxicity and tolerability.

        -  To compare the responses to these treatment regimens with those from first line therapy.

        -  To compare the quality of life.

      OUTLINE: This is a randomized, open-label, parallel group, multicenter study. Patients are
      randomized to 1 of 2 treatment arms.

        -  Arm I (CHOP): Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and
           vincristine IV on day 1 and oral prednisolone on days 1-5. Arm I has been discontinued
           April 2012 on recommendation of the DMC.

        -  Arm II (CHOP with bortezomib): Patients receive bortezomib IV over 3-5 seconds on days 1
           and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1;
           and oral prednisolone on days 1-5.

      In both arms, treatment repeats every 21 days for up to 8 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients complete quality of life questionnaires at baseline, prior to each treatment course,
      and then at 30 days after completion of treatment.

      After completion of study treatment, patients are followed at 30 days and then every 12 weeks
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>30 days and every 12 weeks</time_frame>
    <description>The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unacceptable toxicity or tolerability as assessed by NCI CTCAE v3.0</measure>
    <time_frame>continual after first drug dose</time_frame>
    <description>The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.
Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.
After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of mantle cell lymphoma (MCL)

               -  Expression of cyclin D1 or evidence of t(11;14) translocation by cytogenetics,
                  FISH, or polymerase chain reaction

          -  Refractory to or relapsed or progressed after first line antineoplastic therapy

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2

          -  ANC ≥ 1,000/mm³ (not related to lymphoma)

          -  Platelet count ≥ 30,000/mm³

          -  AST and ALT ≤ 3 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 2 times ULN

          -  Creatinine clearance ≥ 20 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Known serological positivity for HBV, HCV, or HIV

          -  History of allergic reaction attributable to compounds containing boron or mannitol

          -  Diagnosed or treated for a malignancy other than MCL within the past 5 years except
             for completely resected basal cell or squamous cell carcinoma of the skin or any in
             situ malignancy

          -  Active systemic infection requiring treatment

          -  Serious medical or psychiatric illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  Toxic effects of prior therapy or surgery must be resolved to ≤ grade 2

          -  Prior splenectomy or localized radiotherapy allowed

          -  Any prior chemotherapy regimen allowed

               -  Chemotherapy may have been given in combination with rituximab

          -  Concurrent enrollment in a nontreatment study allowed, provided it does not interfere
             with participation in this study

        Exclusion criteria:

          -  Prior bortezomib

          -  Antineoplastic therapy within the past 3 weeks

          -  Nitrosoureas within the past 6 weeks

          -  Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody within
             the past 4 weeks

          -  Radiotherapy within the past 3 weeks

          -  Major surgery within the past 2 weeks

          -  Concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Rule, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Derriford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Hope Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B75 7RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <state>England</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <state>England</state>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>England</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>England</state>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>England</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Prescot Merseyside</city>
        <state>England</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <state>England</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>England</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>England</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro, Cornwall</city>
        <state>England</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <state>Scotland</state>
        <zip>1V2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <state>Wales</state>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Philip Hospital</name>
      <address>
        <city>Llanelli</city>
        <state>Wales</state>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. doi: 10.1111/bjh.13101. Epub 2014 Aug 22.</citation>
    <PMID>25146720</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

